Angiogenesis, the formation of new vessels from preexisting parent vessels, is a critical factor in growth and dissemination of primary tumours ([@bib13]). During the multi-step development of cancer, tumour cells exploit the pathways controlled by angiogenic growth factors and their receptors in order to sustain expanding growth ([@bib18]). Hepatocyte growth factor (HGF), also known as scatter factor, has mitogenic and motogenic effects on target epithelial and endothelial cells via its receptor c-Met ([@bib31]). Overproduction of HGF by tumour cells or tumour-associated stromal cells and increased expression of the c-Met protein are two mechanisms that contribute to aberrant stimulation of this pathway. Consequences of dysregulated HGF and c-Met expression include tumour cell migration, proliferation, and protection from apoptosis ([@bib8]). Overexpression of HGF and c-Met is common in numerous cancer types and is associated with worse prognosis ([@bib5]). In addition, other pro-angiogenic factors secreted from tumour cells have been shown to induce HGF production through autocrine and paracrine mechanisms ([@bib24]; [@bib23]). In several human cancer cell lines, basic fibroblast growth factor (bFGF) has been shown to be a potent stimulator of HGF production from stromal fibroblasts, promoting a cycle of continued growth and motility of tumour cells through HGF/c-Met activation ([@bib24]; [@bib23]; [@bib31]).

High-grade endometrial cancer (EC) subtypes, including high-grade endometrioid (EM), clear cell (CC), and papillary serous (PS), account for a disproportionate number of EC-related deaths each year ([@bib17]). The role of angiogenic biomarkers in EC prognosis generally has been limited to EM tumours, although one previous study examined co-expression of HGF and c-Met in 38 PS cases; overall survival (OS) was significantly worse among the patients with strong HGF or strong c-Met expression, although no association between staining, myometrial invasion, or lymph-node involvement was observed ([@bib6]). In a case-series of 93 EM EC patients, [@bib28] reported that c-Met expression was significantly associated with advanced stage, poor differentiation, and worse OS, whereas HGF was significantly associated with advanced stage. Neither c-Met nor HGF expression was an independent prognostic factor for survival in these EM cases ([@bib28]). Two studies of associations between bFGF expression and tumour characteristics in EM EC patients have shown that strong expression of tumour-derived bFGF is significantly associated with high-grade tumours, presence of tumour necrosis, vascular invasion, and advanced stage tumours ([@bib14]; [@bib25]). Furthermore, bFGF has been shown to significantly increase HGF transcription in EC cell lines ([@bib31]).

This evidence suggests that bFGF expression is associated with aggressive endometrial tumour characteristics and is a potent inducer of HGF/c-Met interactions in EC cell lines. Whether or not bFGF is prognostically relevant for EC patients requires further investigation. Here, we examine the co-expression of bFGF, HGF, and c-Met in a histologically diverse sample of EC cases using immunohistochemistry (IHC). As divergent prognostic roles have been attributed to tumour and stromal expression of angiogenic biomarkers in other cancer sites, we evaluated these compartments separately ([@bib10]; [@bib3]). Our primary hypothesis is that tumour expression of the markers would be associated with worse survival, whereas stromal expression would be associated with better survival.

Materials and methods
=====================

Study sample
------------

EC cases included in this study were treated at Magee-Womens Hospital in Pittsburgh, PA, between 1996 and 2008. Of 1486 eligible cases, we randomly sampled 211 cases using a stratified random sampling design. The cohort of eligible cases has been described previously ([@bib12]). Histology subtype (EM (any grade) and non-EM (CC+PS)) and International Federation of Gynecology and Obstetrics (FIGOs) stage (stage I, stage II, stage III, and stage IV) defined the eight sampling strata within which simple random samples were drawn. Among the EM cases, our sample included 33 stage I, 29 stage II, 37 stage III, and 15 stage IV cases. Among non-EM cases, our sample included 40 stage I, 9 stage II, 26 stage III, and 22 stage IV cases. Our goal was to include 25 cases per stratum, however, because of insufficient tumour blocks in certain strata, larger strata were oversampled. This study was approved by the University of Pittsburgh Institutional Review Board. At the time of surgery, all the patients provided written informed consent for use of tissue samples in future research studies.

IHC
---

Formalin-fixed, paraffin-embedded archival tissue samples were retrieved from the 211 sampled cases. Tissue material was collected from the primary tumour; metastatic tissues were not available for this study. Prior to slide sectioning, tissue blocks and matching hematoxylin- and eosin-stained slides were reviewed by one expert gynaecologic pathologist to select tumour regions with ample tumour and stromal material. The slides were deparaffinised and hydrated with xylenes and washed with progressively decreasing alcohol concentrations. Endogenous peroxidase activity was blocked with 3% methanol peroxide. After antigen retrieval in 0.01 ℳ boiling citrate buffer (pH 6.0) in a microwave, non-specific staining was blocked with protein block (Dako North America, Inc, Carpinteria, CA, USA). Whole-tissue sections were incubated for 1 h at room temperature with 100 *μ*l of polyclonal HGF antibody (R&D Systems, Minneapolis, MN, USA, dilution 1 : 30), polyclonal c-Met antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA, dilution 1 : 75), and polyclonal bFGF antibody (Millipore, Billerica, MA, USA, dilution 1 : 1000). Slides were subsequently rinsed in PBS/Tween solution for 5 min followed by incubation with a polymer (ImmPRESS Universal reagent; Vector Laboratories, Burlingame, CA, USA) followed by development with diaminobenzidine for detection. Slides were counterstained with Shandon Hematoxylin for 2 min, rinsed in several concentrations of alcohol solution, mounted, and viewed. Positive and negative controls were run with each batch of approximately 40 slides. Placenta, fibroadenoma, and granulation tissue were the positive controls for HGF, c-Met, and bFGF, respectively. Omission of the primary antibody was used to control for any immunoreactivity due to secondary antibody alone. Cytoplasmic and nuclear immunostaining was observed for HGF and bFGF; cytoplasmic staining was observed for c-Met. To validate our IHC findings, we randomly selected a subset of 20 cases for re-analysis. New slides were cut from tumour blocks and stained with antibodies. This subset of slides was evaluated without knowledge of the previously recorded scores and the intra-rater agreement was 100%.

IHC expression of tumour and stromal HGF, c-Met, and bFGF was initially evaluated using a semi-quantitative score. The intensity of staining (0=none, 1=weak, 2=moderate, and 3=strong) and the proportion of positive-staining cells (1=1--5%, 2=6--20%, 3=21--80%, and 4=\>80%) were summed to calculate the cumulative score. Acceptable values of the cumulative score are 0, 2, 3, 4, 5, 6, and 7. As the prevalence of positive expression scores (cumulative scores 2--7) was low for HGF and c-Met, we chose to categorise expression as negative (0) *vs* positive (2--7). An expert gynaecologic pathologist blinded to survival outcomes evaluated all the slides. Furthermore, tumour and stromal localisation was analysed from a single slide. Stromal expression of HGF and c-Met was negative in all cases, whereas bFGF expression was apparent in the tumour and stroma.

Statistical analyses
--------------------

Associations between HGF, c-Met, bFGF, and clinicopathological variables and associations between pair of biomarkers were assessed using Chi-square tests. OS and recurrence-free survival (RFS) were quantified as the number of days between the date of diagnosis and the date of death from all the causes or date of recurrence, respectively. Patients who did not experience either outcome were censored at the last date of contact or the date of last follow-up (December 31, 2008). RFS analyses included only cases that were known to be disease-free following the primary surgery. Kaplan--Meier estimates of OS and RFS and log-rank tests were used to compare survival distributions by biomarker expression status.

Associations between HGF, c-Met, and bFGF and survival outcomes were adjusted for histology subtype, FIGO stage, and age using Cox proportional hazards models. In addition to main effect models, we examined pairwise interactions between the biomarkers. All the Cox model analyses were stratified by year of diagnosis. Sampling weights were calculated as the inverse probability of being selected into this study from the larger sampling frame, given the availability of tumour blocks. In Stata 11, the svy family of commands was used to incorporate sampling weights (StataCorp LP, College Station, TX, USA).

Results
=======

Examples of the IHC expression of HGF, c-Met, and bFGF (tumour and stromal) are shown in [Figure 1](#fig1){ref-type="fig"}. Positive expression of HGF, c-Met, tumour bFGF, and stromal bFGF was observed in 31 (15%), 56 (26%), 35 (16%), and 116 (55%) cases, respectively.

No significant associations were observed between HGF or c-Met expression and any of the clinicopathological factors shown in [Table 1](#tbl1){ref-type="table"} (*P*\>0.12 for each). Tumour bFGF was significantly associated with histology type, FIGO stage, lymph-node involvement, and metastasis. Compared with low-grade EM cases (1%), positive tumour bFGF expression was significantly more common in high-grade EM (32%), CC (32%), and PS cases (16%). Advanced FIGO stage cases had a significantly higher prevalence of positive tumour bFGF expression (18%) than early-stage cases (5%). Additionally, tumour bFGF expression was higher in cases with positive lymph-node involvement (33%) compared with cases with negative lymph-node involvement (8%) or no nodal examination (2%), and significantly more common among metastatic cases (24%) than among non-metastatic cases (6%). Stromal bFGF was borderline significantly associated with histology subtype (*P*=0.06). Stromal bFGF expression was more common among CC cases (70%), high-grade EM (61%), and low-grade EM (59%) compared with PS cases (44%). When examining the association between pairs of biomarkers, only HGF and c-Met were significantly associated with each other. c-Met positivity was significantly higher among cases with positive HGF expression (63%) compared with cases with negative HGF expression (15%, *P*=0.03, data not tabled).

Median follow-up time was 1287 days in the sample (range: 24--4659 days) and 1413 days in the sampling frame (range: 1--4887 days). Overall, patients with positive tumour bFGF expression had significantly worse OS (*P*=0.009) and RFS (*P*\<0.001) compared with patients with negative tumour bFGF expression ([Table 2](#tbl2){ref-type="table"}; [Figures 2A and B](#fig2){ref-type="fig"}). HGF, c-Met, and stromal bFGF expression were not significantly associated with OS or RFS.

In the multivariable Cox proportional hazards models, we observed significant interactions between HGF and stromal bFGF expression for OS (*P*=0.02, degrees of freedom=1) and between HGF and tumour bFGF for RFS (*P*=0.007, degrees of freedom=1; [Table 3](#tbl3){ref-type="table"}, [Figure 3](#fig3){ref-type="fig"}). Relative to cases who were negative on both biomarkers, the hazard of death was nonsignificantly elevated for HGF-positive, stromal bFGF-negative cases (HR=2.09) and nonsignificantly reduced for HGF-positive, stromal bFGF-positive cases (HR=0.29). However, HGF-positive, stromal bFGF-positive cases had a significantly reduced risk of death compared with HGF-positive, stromal bFGF-negative cases (HR: 0.29/2.09=0.14, 95% CI 0.03, 0.60). Among the 18 cases with HGF-positive, stromal bFGF-positive expression, 10 had low-grade EM tumours, 9 had early-stage tumours, and 15 had no evidence of metastases (data not tabled).

In the RFS model ([Table 3](#tbl3){ref-type="table"}), based on very small numbers HGF-positive, tumour bFGF-positive patients had an almost 10 times higher risk of recurrence compared with patients with negative expression of both biomarkers (HR: 9.88, 95% CI 2.63, 37.16), whereas HGF-positive, tumour bFGF-negative patients had a significantly lower risk of recurrence (HR: 0.07, 95% CI 0.00, 0.81). Among the five cases with an HGF-positive, tumour bFGF-positive expression pattern, four had either a CC or PS tumour, two had late-stage tumours, and two had evidence of metastases (data not tabled).

Discussion
==========

We examined the expression of HGF, c-Met, and bFGF using IHC in a large sample of EC cases and correlated expression with clinicopathological factors and patient outcomes. OS was significantly associated with stromal bFGF expression in the presence of HGF expression. Specifically, HGF-positive, stromal bFGF-positive patients had significantly better OS compared with HGF-positive, stromal bFGF-negative patients. The small group of patients who were HGF-positive, tumour bFGF-positive had almost a 10 times higher risk of recurrence compared with tumour HGF-negative, tumour bFGF-negative patients. Additionally, patients who were HGF-positive and tumour bFGF-negative had a significantly reduced risk of recurrence compared with HGF-negative, tumour bFGF-negative patients. To our knowledge, this is the first study to indicate prognostic significance of these angiogenic factors in EC patients.

Interactions between tumour cells and tumour-associated stromal cells are hypothesised to have a role in aggressive cancer phenotypes. The host stromal response is activated initially to eliminate tumour cells; however, tumour cells co-opt the functions of recruited stromal cells to enhance the growth and invasion of the tumour, resulting in a tumour-supportive stroma ([@bib9]; [@bib21]). Furthermore, as the metabolic demand for nutrients increases, tumour cells activate angiogenesis through secretion of various cytokines. Therefore, understanding the role of the tumour- and stromal-derived angiogenic pathways is important for targeted therapy strategies ([@bib20]; [@bib1]; [@bib7]).

The underlying mechanism describing a protective role of stromal-derived bFGF is unknown. This study, along with others, has noted that angiogenic proteins expressed in the stroma have a divergent prognostic role compared with tumour expression of the same proteins. In two independent non-small cell lung cancer (NSCLC) cohorts, stromal bFGF expression was inversely associated with lymph-node metastasis, advanced stage, and disease-specific mortality, indicating a potentially protective role of this cytokine ([@bib16]; [@bib3]). Conversely, [@bib27] reported that tumour bFGF expression was significantly associated with poor prognosis in NSCLC patients. In another NSCLC cohort, [@bib10] reported that stromal expression of vascular endothelial growth-factor ligands and receptors was associated with better survival in NSCLC patients, whereas tumour expression of the same biomarkers was associated with worse prognosis.

Our findings agree with the body of literature reporting an association between tumour bFGF expression, aggressive clinicopathological characteristics, and poor prognosis in various cancers ([@bib29]; [@bib11]; [@bib26]; [@bib4]; [@bib2]). In this study, tumour bFGF was significantly associated with aggressive endometrial histology subtypes, advanced stage, positive lymph-node involvement, and worse RFS. We propose that a delicate balance between tumour-inhibiting and tumour-promoting effects of bFGF may exist: although the host stroma controls expression of bFGF, anti-cancer effects may be dominant; however, when the tumour becomes independent of stromal paracrine factors through the establishment of autocrine bFGF stimulation, poor outcomes are more likely to occur.

We also observed a statistically significant association between HGF and c-Met expression. The biological effects of HGF are mediated by the c-Met receptor, which is frequently overexpressed in many human cancers ([@bib5]). Upon HGF binding, c-Met activates a number of cellular responses, including motility or scattering of epithelial cells, proliferation, and invasion ([@bib5]). Despite the importance of HGF in c-Met activation, most prognostic studies focus solely on the aberrant expression of c-Met. In fact, development and implementation of HGF antagonists lag far behind the use of c-Met inhibitors currently used in clinical trials ([@bib30]). Evaluation of the co-expression of HGF and c-Met may lead to a better understanding of the overall importance of this signalling pathway in cancer prognosis.

Strengths of this study include high quality pathology data, discrimination between tumour and stromal expression of the biomarkers, and an evaluation of the prognostic role of this biomarker pathway using multivariable methods, with appropriate weighting for tumour-block availability within the sampling frame. Despite including 211 EC patients, the major limitation of this study is the sample size, particularly the small number of HGF-positive patients in the RFS analysis. Furthermore, the prevalence of positive HGF and c-Met expression in our study is lower than previously published EC studies. We observed positive HGF and c-Met expression in 15% and 22% of EC cases compared with 90% and 63% of the tumours in the Wagatsuma series and 100% and 87% of PS EC cases in the Bishop series, respectively ([@bib28]; [@bib6]). The low positive prevalence of biomarkers in our study may reflect variations in IHC procedures across laboratories, subjective assessment of the IHC slides, or differences in case selection. We note that our study sample was selected based on tumour characteristics (stage and histology subtype), which differs from the use of consecutively treated EM EC cases as in the Wagatsuma series or serous EC cases included in the Bishop series. Additionally, our use of whole-section slides rather than tissue microarrays may have contributed to differences between our study and Bishop *et al.*

In addition to replicating the results of this study, future examinations of bFGF should examine the mechanisms that could explain the apparently protective role of stromal expression. Functional studies that can provide a biological rationale for our observed associations would be useful in recommending molecularly targeted therapies. Recent evidence supports a role for therapeutic targeting of the normal cells that surround the primary tumour, that is, the tumour microenvironment ([@bib20]; [@bib19]). Compared with neoplastic cells, which are characterised by genetic mutations, cells of the microenvironment are genetically stable and may provide a more attractive therapeutic target. Several novel agents targeting HGF and bFGF, including AMG102 and AZD4547, respectively, are currently in phase I and II clinical trials ([@bib15]; [@bib22]).

In summary, this study suggests the presence of a significant interaction between HGF and bFGF expression in EC survival. The different association between survival and tumour *vs* stromal expression of bFGF is indicative of this marker\'s diverse role in tumour physiology and has potential implications for targeted therapies.
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![Representative IHC stains showing (**A**) negative HGF expression, (**B** and **C**) positive HGF expression, (**D**) negative c-Met expression, (**E** and **F**) positive c-Met, (**G**) negative bFGF expression, (**H**) positive tumour bFGF expression, and (**I**) positive stromal bFGF expression.](bjc2012200f1){#fig1}

![Kaplan--Meier curves of (**A**) OS and (**B**) RFS by tumour bFGF status.](bjc2012200f2){#fig2}

![Kaplan--Meier curves of (**A**) OS by HGF and stromal bFGF and (**B**) RFS by HGF and tumour bFGF.](bjc2012200f3){#fig3}

###### Associations between HGF, c-Met, and bFGF expression and clinicopathological factors

                                                     **Positive expression,** ***n***[a](#t1-fn1){ref-type="fn"} **(%)**[b](#t1-fn2){ref-type="fn"}                       
  --------------------------------------- ---------- ------------------------------------------------------------------------------------------------ --------- --------- ----------
  *Age*                                                                                                                                                                   
   \<65 years                             118 (56)   15 (12)                                                                                          31 (26)   17 (3)    65 (60)
   ⩾65 years                              93 (44)    16 (19)                                                                                          25 (15)   18 (14)   51 (58)
   *P*-value[d](#t1-fn4){ref-type="fn"}              0.49                                                                                             0.28      0.11      0.90
                                                                                                                                                                           
  *Race*                                                                                                                                                                  
   White                                  189 (90)   29 (15)                                                                                          50 (23)   32 (7)    106 (61)
   Non-White                              22 (10)    2 (4)                                                                                            6 (13)    3 (8)     10 (32)
   *P*-value[d](#t1-fn4){ref-type="fn"}              0.18                                                                                             0.45      0.88      0.29
                                                                                                                                                                           
  *Body Mass Index (BMI)*                                                                                                                                                 
   Normal (BMI \<25 kg m^−2^)             55 (26)    11 (24)                                                                                          14 (33)   10 (5)    28 (49)
   Overweight (BMI 25-30 kg m^−2^)        60 (28)    9 (14)                                                                                           20 (28)   11 (8)    36 (52)
   Obese (BMI \>30 kg m^−2^)              96 (46)    11 (10)                                                                                          22 (14)   14 (8)    52 (67)
   *P*-value[d](#t1-fn4){ref-type="fn"}              0.57                                                                                             0.29      0.63      0.43
                                                                                                                                                                           
  *Histology type*                                                                                                                                                        
   Low-grade EM                           80 (38)    14 (16)                                                                                          12 (19)   4 (1)     47 (59)
   High-grade EM                          34 (16)    2 (2)                                                                                            11 (35)   10 (32)   18 (61)
   Clear cell                             31 (15)    6 (18)                                                                                           8 (26)    10 (32)   21 (70)
   Papillary serous                       66 (31)    9 (13)                                                                                           25 (37)   11 (16)   30 (44)
   *P*-value[d](#t1-fn4){ref-type="fn"}              0.12                                                                                             0.20      \<0.001   0.06
                                                                                                                                                                           
  *FIGO stage*                                                                                                                                                            
   Early stage (I and II)                 111 (53)   15 (15)                                                                                          26 (21)   15 (5)    59 (59)
   Late stage (III and IV)                100 (47)   16 (14)                                                                                          30 (28)   20 (18)   57 (59)
   *P*-value[d](#t1-fn4){ref-type="fn"}              0.97                                                                                             0.39      0.008     0.99
                                                                                                                                                                           
  *Lymph-node involvement*                                                                                                                                                
   Negative                               109 (52)   18 (20)                                                                                          27 (22)   16 (8)    60 (59)
   Positive                               40 (19)    3 (6)                                                                                            13 (28)   13 (33)   28 (70)
   No nodes examined                      51 (24)    7 (7)                                                                                            12 (21)   6 (2)     24 (58)
   Unknown                                11 (5)     3 (35)                                                                                           4 (24)    0 (0)     4 (32)
   *P*-value[d](#t1-fn4){ref-type="fn"}              0.19                                                                                             0.92      0.002     0.25
                                                                                                                                                                           
  *Metastasis*                                                                                                                                                            
   No                                     174 (82)   23 (14)                                                                                          45 (22)   25 (6)    98 (59)
   Yes                                    37 (18)    8 (22)                                                                                           11 (28)   10 (24)   18 (48)
   *P*-value[d](#t1-fn4){ref-type="fn"}              0.38                                                                                             0.49      0.002     0.30

Sample count.

Weighted proportion in the sampling frame, *n*=1486.

Unweighted proportion in the study sample, *n*=211.

Adjusted Wald\'s *P*-value.

###### Summary of mortality and recurrence by HGF, c-Met, tumour bFGF, and stromal bFGF status

  **Biomarker expression**   **Deaths/*****n*** **(87/211)**   ***P*****-value**    **Recurrences/*****n*** **(42/174)**  ***P*****-value**[\*](#t2-fn1){ref-type="fn"}
  -------------------------- --------------------------------- ------------------- -------------------------------------- -----------------------------------------------
  *HGF*                                                        0.96                                                       0.21
   Negative                  76/180                                                                38/150                  
   Positive                  11/31                                                                  4/24                   
                                                                                                                           
  *c-Met*                                                      0.48                                                       0.14
   Negative                  61/155                                                                28/130                  
   Positive                  26/56                                                                 14/44                   
                                                                                                                           
  *Tumour bFGF*                                                0.009                                                      \<0.001
   Negative                  67/176                                                                30/147                  
   Positive                  20/35                                                                 12/27                   
                                                                                                                           
  *Stromal bFGF*                                               0.83                                                       0.22
   Negative                  43/95                                                                 19/75                   
   Positive                  44/116                                                                23/99                   

*P*-values based on log-rank statistics.

###### Cox proportional hazards model for overall survival and recurrence-free survival showing interactions between HGF and stromal bFGF and HGF and tumour bFGF, respectively

  **Overall Survival (*****n*****=211)**                   **Deaths/*****n***         **HR (95% CI)**[a](#t3-fn1){ref-type="fn"}   ***P***[b](#t3-fn2){ref-type="fn"}
  ------------------------------------------------ ---------------------------------- -------------------------------------------- ------------------------------------
  *HGF and stromal bFGF expression*                 0.05[c](#t3-fn3){ref-type="fn"}                                                
   HGF-negative, stromal bFGF-negative                           36/82                1.00 (Reference)                              
   HGF-positive, stromal bFGF-negative                            7/13                2.09 (0.83, 5.25)                            0.12
   HGF-negative, stromal bFGF-positive                           40/98                1.00 (0.44, 2.28)                            1.00
   HGF-positive, stromal bFGF-positive                            4/18                0.29 (0.06, 1.33)                            0.11
                                                                                                                                    
  **Recurrence-free survival (*****n*****=174)**        **Recurrences/*****n***       **HR (95% CI)**[a](#t3-fn1){ref-type="fn"}   ***P***[b](#t3-fn2){ref-type="fn"}
  *HGF and tumour bFGF expression*                  0.001[c](#t3-fn3){ref-type="fn"}                                               
   HGF-negative, tumour bFGF-negative                            29/128               1.00 (Reference)                              
   HGF-positive, tumour bFGF-negative                             1/19                0.07 (0.00, 0.81)                            0.03
   HGF-negative, tumour bFGF-positive                             9/22                1.56 (0.44, 5.53)                            0.49
   HGF-positive, tumour bFGF-positive                             3/5                 9.88 (2.63, 37.16)                           0.001

Adjusted for c-Met, stage, histology subtype, and age; stratified by year of diagnosis.

Adjusted Wald\'s *P*-value.

Three degree of freedom *P*-value for heterogeneity.
